Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Chinese and Japanese Male Volunteers (Randomised, Single-blind, Placebo-controlled Trial)
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs BI 685509 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Sep 2017 Planned End Date changed from 10 Mar 2018 to 31 Mar 2018.
- 22 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 New trial record